[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-339572-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-339572-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","thoracic-lymphangitis-as-an-immune-related-adverse-event-a-case-report","Thoracic lymphangitis as an immune-related adverse event - a case report","","Immune checkpoint inhibitors (ICIs) are increasingly used perioperatively for lung cancer, but immune-related adverse events (irAEs) can interrupt therapy. A case is reported in which thoracic lymphangitis emerged after postoperative ICI treatment. The patient developed breathlessness and rapidly progressed to hypoxia grade 3, with chest CT showing marked lymphostasis. High-dose steroid therapy improved symptoms, highlighting the need to recognize and monitor thoracic lymphangitis as ICI use expands in neoadjuvant, adjuvant, and perioperative settings.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/thoracic-lymphangitis-as-an-immune-related-adverse-event-a-case-report/339572/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/thoracic-lymphangitis-as-an-immune-related-adverse-event-a-case-report/339572.png","ImageObject",300,407,{"name":42,"@type":43},"Maeve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What immune-related adverse event was reported after ICI therapy?","Question",{"text":63,"@type":64},"Thoracic lymphangitis (thoracic lymphangitis) occurred after postoperative ICI treatment for lung cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What symptoms and imaging findings characterized the case?",{"text":68,"@type":64},"The patient developed breathlessness that rapidly progressed to hypoxia grade 3, and chest CT revealed significant lymphostasis mainly in the right lower lobe.",{"name":70,"@type":61,"acceptedAnswer":71},"How was the adverse event treated and what was the outcome?",{"text":72,"@type":64},"High-dose methylprednisolone was started, leading to complete improvement on day 8 and allowing steroid discontinuation without recurrence.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},339572,1790164140,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":30,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":55,"preview_page_count":30,"preview_urls":144},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","Kobayashi BMC Pulmonary Medicine (2024) 24:299  \n[https://doi.org/10.1186/s12890-024-03123-5](https://doi.org/10.1186/s12890-024-03123-5)  \nBMC Pulmonary Medicine  \n CASE REPORT Open Access  \nThoracic lymphangitis as an immune-related   adverse event: a case report  \nHaruki Kobayashi 1*  \nAbstract  \nThe efficacy of immune checkpoint inhibitors (ICIs) has been widely recognized in several cancers and is now being used in the perioperative setting for lung cancer.  \nWe recently encountered an immune-related adverse event that has not been previously reported: thoracic lymphangitis, which occurred after postoperative ICI treatment for lung cancer. The patient complained of breathlessness and her condition rapidly progressed to hypoxia grade 3. Chest computed tomography revealed significant lymphostasis. With high-dose steroid treatment, the patient showed improvement.  \nTherefore, as the frequency of neoadjuvant, adjuvant, and perioperative ICI use is expected to increase, it is crucial to understand and monitor this adverse event.  \nKeywords Immune-related adverse event, Thoracic lymphangitis, Non-small cell lung cancer  \nBackground  \nThe efficacy of immune checkpoint inhibitors (ICIs) has been widely recognized for several cancers, and they are now being used in the perioperative setting for lung cancer [1–4], whereas there is a certain proportion of patients who experience adverse events that prevent them from continuing treatment [5, 6]. It is predicted that unexperienced immune-related adverse event (irAE) may occur by administering ICIs in a larger number of cancer patients.  \nObjective  \nWe report a novel irAE occurring after postoperative adjuvant chemotherapy for lung cancer.  \n*Correspondence: Haruki Kobayashi [h.kobayashi@scchr.jp](h.kobayashi@scchr.jp)  \n1 Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Shizuoka, Nagaizumi-Cho Sunto-Gun 411-8777, Japan  \nCase report  \nA 65-year-old woman developed postoperative chylothorax after undergoing left upper lobectomy with wedge bronchoplasty with ND2a-2 for left upper lobe lung cancer. Decreasing dietary fatty acids did not improve her condition; however, lymphangiography with lipiodol closed the leak. Thereafter, the patient was treated for p-stage IIIA non-small cell lung cancer with tumor cell PD-L1 expression 20%(22C3) with four cycles of postoperative adjuvant chemotherapy regimens of cisplatin and vinorelbine on the 59th day postsurgery. Computed tomography (CT) results were normal without recurrence (Fig. 1 A). Based on the IMpower010 trial, atezolizumab was administered. After day 9 of cycle 1, she developed fever in between grade 1 to 2. On day 15, she complained of breathlessness and her condition rapidly progressed to hypoxia grade 3. Chest CT conducted on the same day revealed significant lymphostasis mainly located in right lower lobe (Fig. 1 B–E). Occurrence of lymphangitis carcinomatosa, infectious diseases, and heart failure were ruled out. The patient was diagnosed with lymphangitis, an irAE, due to blockage of the thoracic duct by chylothorax treatment and activation of  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](h","cbCaiggdWLQOaaiL","https://ap.wps.com/l/cbCaiggdWLQOaaiL","pdf",901336,"English","# Abstract\n# Background\n# Objective\n# Case report\n## Clinical course\n# Discussion\n## Proposed causes","[{\"question\":\"What immune-related adverse event was reported after ICI therapy?\",\"answer\":\"Thoracic lymphangitis (thoracic lymphangitis) occurred after postoperative ICI treatment for lung cancer.\"},{\"question\":\"What symptoms and imaging findings characterized the case?\",\"answer\":\"The patient developed breathlessness that rapidly progressed to hypoxia grade 3, and chest CT revealed significant lymphostasis mainly in the right lower lobe.\"},{\"question\":\"How was the adverse event treated and what was the outcome?\",\"answer\":\"High-dose methylprednisolone was started, leading to complete improvement on day 8 and allowing steroid discontinuation without recurrence.\"}]","Thoracic lymphangitis as an immune-related adverse event - a case report | PDF",1790031061,[145,149,153],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e1620b0b680fb0c340810b5d55d8ccf6.webp",983,1305,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d729329e266b48fb94cbec301b5c8a4c.webp",982,1304,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a6286c8fb428a750d14e37cedd5406b.webp",981,1303]